Transgenomic Acquires Clinical Sample Biorepository from Gene Logic
News Jun 01, 2012
The biorepository contains thousands of human biological samples that can be used to validate diagnostic assays developed by Transgenomic. Transgenomic will use the samples to develop and validate its REVEAL family of proprietary ICE COLD-PCR-based oncology assays, as well as its WAVE MCE System and SURVEYOR® Scan Mutation Detection Kits.
“This transaction significantly strengthens Transgenomic’s position in translational medicine services, providing a deep source of clinical samples allowing us to validate new drug-associated genetic targets,” said Craig Tuttle, Chief Executive Officer of Transgenomic. “The biorepository provides not only strategic and operational benefits, but also long-term cost savings. Acquiring specimens on a case-by-case basis is expensive and time-consuming; such expenditure would quickly surpass the cost of acquiring this asset.”
The Gene Logic biorepository consists of a high quality, diverse collection of human tissue samples and extracted DNA specimens with linked clinical information. The 60,000 samples and specimens cover multiple disease areas, including many thousands of cancer tissue specimens.
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
Cellular Judge Rules on Fate of mRNAs under Sugar StressNews
A newly discovered protein, Puf5P, has been shown to arbitrate on which mRNAs are stored and which are destroyed.READ MORE
Peli BioThermal Hires Dominic Hyde as New VP of Crēdo™ on DemandNews
Radical expansion of global rental program includes adding staff, locations and doubling their container inventory.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018